- Home
- RVMD vs PODD Comparison
RVMD vs PODD Comparison
Compare RVMD & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RVMD | PODD |
|---|---|---|
| Founded | 2014 | 2000 |
| Country | United States | United States |
| Employees | 883 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.2B | 17.0B |
| IPO Year | N/A | 2007 |
Fundamental Metrics
Financial Performance| Metric | RVMD | PODD |
|---|---|---|
| Price | $147.38 | $200.51 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 19 | 20 |
| Target Price | $135.05 | ★ $349.80 |
| AVG Volume (30 Days) | ★ 2.4M | 785.7K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 3.48 |
| Revenue | N/A | ★ $2,708,100,000.00 |
| Revenue This Year | N/A | $24.59 |
| Revenue Next Year | $411.49 | $19.18 |
| P/E Ratio | ★ N/A | $57.88 |
| Revenue Growth | N/A | ★ 30.73 |
| 52 Week Low | $34.00 | $194.61 |
| 52 Week High | $148.00 | $354.88 |
Technical Indicators
Market Signals| Indicator | RVMD | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 86.50 | 31.16 |
| Support Level | $93.39 | N/A |
| Resistance Level | N/A | $299.75 |
| Average True Range (ATR) | 4.43 | 6.69 |
| MACD | 4.88 | -0.01 |
| Stochastic Oscillator | 98.09 | 20.92 |
Price Performance
Historical ComparisonAbout RVMD Revolution Medicines Inc.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.
About PODD Insulet Corporation
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.